<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854565</url>
  </required_header>
  <id_info>
    <org_study_id>Decorin-ARDS fibrosis study</org_study_id>
    <nct_id>NCT03854565</nct_id>
  </id_info>
  <brief_title>Glycocalyx Biomarkers in ARDS for Clinical Prognosis and Pulmonary Fibrosis</brief_title>
  <official_title>Predictive Value of Glycocalyx Biomarkers in Mechanical Ventilation of Patients With ARDS for Clinical Prognosis and Long-term Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ARDS is a severe disease in ICU, and could induce high mortality. Glycocalyx is an important
      matrix construction which covers endothelial cells, it could protect endothelial cells injury
      and the glycocalyx biomarkers could predict pulmonary injury.

      Decorin is a member of the small leucine-rich proteoglycan (SLRP) family, contains a single
      glycosaminoglycan (GAG) chain and a core protein with 12 leucine-rich repeats. In the
      previous study, decorin is associated with cardiac and liver fibrosis, however, the effects
      of decorin on ARDS pulmonary fibrosis have not been clarified.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>28 days mortality from patients involved in the study</measure>
    <time_frame>28 days</time_frame>
    <description>28 days mortality from patients involved in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CT and syndecan-1 to evaluate pulmonary fibrosis</measure>
    <time_frame>1mon, 3mon and 6 month</time_frame>
    <description>pulmonary fibrosis evaluated by biomarker and CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function test to evaluate pulmonary function</measure>
    <time_frame>1mon, 3mon and 6 month</time_frame>
    <description>pulmonary function evaluated by pulmonary function test</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">336</enrollment>
  <condition>ARDS, Human</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Mechanical Ventilation Pressure High</condition>
  <arm_group>
    <arm_group_label>Mild ARDS</arm_group_label>
    <description>patients have mild ARDS according to Berlin definition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate ARDS</arm_group_label>
    <description>patients have moderate ARDS according to Berlin definition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe ARDS</arm_group_label>
    <description>patients have severe ARDS according to Berlin definition</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Glycocalyx measurementï¼Œrespiratory mechanics measurement</intervention_name>
    <description>ELASA measure glycocalyx, measure plateau pressure, driving pressure</description>
    <arm_group_label>Mild ARDS</arm_group_label>
    <arm_group_label>Moderate ARDS</arm_group_label>
    <arm_group_label>Severe ARDS</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients have been diagnosed ARDS with mechanical ventilation, and do not been used
        heparin, molecular heparin, chondroitin sulfuric acid.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18yrs and &lt;80yrs

          2. Meet ARDS Berlin definition

          3. With mechanical ventilation

        Exclusion Criteria:

          1. have chronic pulmonary disease

          2. have use heparin or low molecular heparin or chondroitin sulfuric acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chun C Pan, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongda hospital, Southeast University, Jiangsu, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chun C Pan, Dr</last_name>
    <phone>+862583262550</phone>
    <email>panchun1982@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chun Pan, Dr</last_name>
      <phone>+862583262550</phone>
      <email>panchun1982@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 17, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Chun Pan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>Glycocalyx</keyword>
  <keyword>pulmonary fibrosis</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

